- Evotec ( NASDAQ: EVO ) said its Seattle-based unit Just - Evotec Biologics expanded a multi-year partnership with Alpine Immune Sciences ( NASDAQ: ALPN ) to develop a commercial process for ALPN-303.
- Evotec said ALPN-303 is being developed to treat systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
- The contract is a continuation of the companies first-in-human program initiated in 2020 in which Just - Evotec delivered drug substance materials for Alpine's ongoing phase 1 study and anticipated phase 2 studies of ALPN-303.
- Under the expanded contract, Just - Evotec Biologics will use its data-driven technology platform to develop a commercial manufacturing process for ALPN-303.
- The program includes upstream and downstream process, analytical method, and formulation development with a view to support commercial manufacturing of ALPN?303.
- Commercial process development activities will be undertaken at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington.
- EVO -10.15% to $12.66 premarket Aug. 10
For further details see:
Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303